SPARCL1 and Familial prostate cancer: High expression of SPARCL1 in prostate cancer is associated with better survival, 5 year metastatic disease-free survival of men with loss of SPARCL1 expression had 5 year metastatic disease-free survival of ~ 60% vs. ~ 80% for men with high SPARCL1 expression [16].